Stockreport

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

iBio, Inc.  (IBIO) 
NASDAQ:AMEX Investor Relations: ir.ibioinc.com
PDF Previously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-selective, GLP-1-synergistic weight loss and prevents weight regain follo [Read more]